BR112012026881A2 - compostos orgânicos - Google Patents
compostos orgânicosInfo
- Publication number
- BR112012026881A2 BR112012026881A2 BR112012026881A BR112012026881A BR112012026881A2 BR 112012026881 A2 BR112012026881 A2 BR 112012026881A2 BR 112012026881 A BR112012026881 A BR 112012026881A BR 112012026881 A BR112012026881 A BR 112012026881A BR 112012026881 A2 BR112012026881 A2 BR 112012026881A2
- Authority
- BR
- Brazil
- Prior art keywords
- organic compounds
- receptor
- sert
- prodrugs
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
compostos orgânicos a invenção relaciona-se a particular heterociclo substituído fusionado com gama-carbolinas, suas pró-drogas , na forma de sal livre , sólido , farmaceuticamente aceitável e/ou substancialmente puro como aqui descrito , composições farmacêuticas do mesmo , e métodos de uso no tratamento de doenças envolvendo receptor 5-th~ 2a~, transportador de serotonina (sert) e/ou vias envolvendo sistemas de sinalização do receptor d~ 2~de dopamina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32704910P | 2010-04-22 | 2010-04-22 | |
US36760910P | 2010-07-26 | 2010-07-26 | |
PCT/US2011/000719 WO2011133224A1 (en) | 2010-04-22 | 2011-04-22 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012026881A2 true BR112012026881A2 (pt) | 2017-10-10 |
Family
ID=44834444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012026881A BR112012026881A2 (pt) | 2010-04-22 | 2011-04-22 | compostos orgânicos |
Country Status (12)
Country | Link |
---|---|
US (2) | US8993572B2 (pt) |
EP (1) | EP2560676B8 (pt) |
JP (1) | JP5894574B2 (pt) |
KR (1) | KR101868165B1 (pt) |
CN (1) | CN103209704B (pt) |
BR (1) | BR112012026881A2 (pt) |
CA (1) | CA2796756A1 (pt) |
ES (1) | ES2602503T3 (pt) |
IL (2) | IL222571A (pt) |
MX (1) | MX339805B (pt) |
RU (1) | RU2591194C2 (pt) |
WO (1) | WO2011133224A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112280A1 (en) | 2007-03-12 | 2008-09-18 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
PT2262505E (pt) | 2008-03-12 | 2014-12-16 | Intra Cellular Therapies Inc | Sólidos de gama-carbolinas fusionadas a heterociclos substituídos |
KR20110022631A (ko) | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
CA2796756A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
CN104519886B (zh) * | 2012-04-14 | 2017-09-12 | 细胞内治疗公司 | 有机化合物 |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
CA3148326A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia |
WO2015154025A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3125892A4 (en) * | 2014-04-04 | 2017-12-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3193878B1 (en) | 2014-09-17 | 2021-01-06 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
CN104327066B (zh) * | 2014-09-30 | 2017-05-24 | 华东理工大学 | 快速高效提取卡柏林类生物碱的方法 |
KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
PT3407888T (pt) | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
MX2018011676A (es) | 2016-03-25 | 2018-12-19 | Intra Cellular Therapies Inc | Compuestos organicos. |
US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
WO2017172795A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2017172784A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ-セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
WO2018106916A1 (en) * | 2016-12-07 | 2018-06-14 | Concert Pharmaceuticals, Inc. | Deuterated quinoxaline compounds |
US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP7132939B2 (ja) * | 2017-03-24 | 2022-09-07 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規組成物および方法 |
WO2019023063A1 (en) * | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
WO2019067591A1 (en) * | 2017-09-26 | 2019-04-04 | Intra-Cellular Therapies, Inc. | NEW SALTS AND CRYSTALS |
KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
EP3801527A4 (en) * | 2018-06-08 | 2022-03-30 | Intra-Cellular Therapies, Inc. | NEW METHODS |
CA3106447A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
EP3811371A1 (en) | 2018-06-21 | 2021-04-28 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
JP2021536453A (ja) | 2018-08-31 | 2021-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規方法 |
KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
CN112955124A (zh) | 2018-09-07 | 2021-06-11 | 阿奎蒂夫疗法公司 | 具有精确的活性物溶出谱的口腔膜组合物和剂型 |
US11628171B2 (en) | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
AU2020311894A1 (en) | 2019-07-07 | 2022-01-27 | Intra-Cellular Therapies, Inc. | Novel methods |
CA3159382A1 (en) | 2019-11-01 | 2021-05-06 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
WO2021097247A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions and methods of treatment |
JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
CN116940351A (zh) | 2021-01-15 | 2023-10-24 | 阿奎斯蒂弗医疗股份有限公司 | 前药组合物和治疗方法 |
CA3210706A1 (en) | 2021-03-09 | 2022-09-15 | Alexander Mark Schobel | Dosage forms having equivalent biocomparable profiles |
WO2023225620A1 (en) | 2022-05-18 | 2023-11-23 | Intra-Cellular Therapies, Inc. | Novel methods |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR207799A1 (es) * | 1974-04-01 | 1976-10-29 | Pfizer | Procedimiento para preparar azaciclo(3,4-a)-n-fenilindoles-2-substituidos |
US4001263A (en) * | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
PT729357E (pt) * | 1993-11-19 | 2005-06-30 | Janssen Pharmaceutica Nv | 1,2-bwenzazoles microencapsulados |
RU2167877C2 (ru) * | 1995-05-31 | 2001-05-27 | Эйсай Ко., Лтд. | Производные конденсированных полициклических гетероциклических соединений и способ их получения |
TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
CA2373920A1 (en) | 1999-06-15 | 2000-12-21 | Wei Deng | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
RU2321391C2 (ru) | 2002-07-29 | 2008-04-10 | Алза Корпорейшн | Способы и лекарственные формы для контролируемой доставки палиперидона |
US20040142970A1 (en) | 2002-11-01 | 2004-07-22 | Kathryn Chung | Treatment of hyperkinetic movement disorder with donepezil |
WO2004056324A2 (en) | 2002-12-19 | 2004-07-08 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
RU2258605C2 (ru) * | 2004-02-17 | 2005-08-20 | Общество с ограниченной ответственностью "Новые Строительные Технологии" | Устройство для приготовления и укладки строительных смесей |
US20080280941A1 (en) * | 2004-03-05 | 2008-11-13 | Pierre Lourtie | 8-Phenoxy-Gamma Carboline Derivatives |
BRPI0515528A (pt) | 2004-09-21 | 2008-07-29 | Pfizer Prod Inc | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central |
US20080028094A1 (en) * | 2006-07-31 | 2008-01-31 | Widerthan Co., Ltd. | Method and system for servicing bgm request and for providing sound source information |
WO2008112280A1 (en) | 2007-03-12 | 2008-09-18 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
WO2009097688A1 (en) | 2008-02-05 | 2009-08-13 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
PT2262505E (pt) | 2008-03-12 | 2014-12-16 | Intra Cellular Therapies Inc | Sólidos de gama-carbolinas fusionadas a heterociclos substituídos |
KR20110022631A (ko) | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
CA2796756A1 (en) * | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
CN104519886B (zh) | 2012-04-14 | 2017-09-12 | 细胞内治疗公司 | 有机化合物 |
HUE053159T2 (hu) | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
CA3148326A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia |
-
2011
- 2011-04-22 CA CA2796756A patent/CA2796756A1/en not_active Abandoned
- 2011-04-22 BR BR112012026881A patent/BR112012026881A2/pt not_active IP Right Cessation
- 2011-04-22 US US13/642,652 patent/US8993572B2/en active Active
- 2011-04-22 RU RU2012149633/04A patent/RU2591194C2/ru active
- 2011-04-22 ES ES11772360.1T patent/ES2602503T3/es active Active
- 2011-04-22 EP EP11772360.1A patent/EP2560676B8/en active Active
- 2011-04-22 CN CN201180025403.6A patent/CN103209704B/zh active Active
- 2011-04-22 KR KR1020127030238A patent/KR101868165B1/ko active IP Right Grant
- 2011-04-22 MX MX2012012277A patent/MX339805B/es active IP Right Grant
- 2011-04-22 WO PCT/US2011/000719 patent/WO2011133224A1/en active Application Filing
- 2011-04-22 JP JP2013506138A patent/JP5894574B2/ja active Active
-
2012
- 2012-10-21 IL IL222571A patent/IL222571A/en active IP Right Grant
-
2015
- 2015-02-20 US US14/627,968 patent/US9371324B2/en active Active
-
2016
- 2016-12-15 IL IL249578A patent/IL249578A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2012149633A (ru) | 2014-05-27 |
CN103209704B (zh) | 2017-10-27 |
MX339805B (es) | 2016-06-10 |
US9371324B2 (en) | 2016-06-21 |
ES2602503T3 (es) | 2017-02-21 |
EP2560676A1 (en) | 2013-02-27 |
US20150166540A1 (en) | 2015-06-18 |
MX2012012277A (es) | 2013-04-03 |
US8993572B2 (en) | 2015-03-31 |
KR20130055610A (ko) | 2013-05-28 |
EP2560676A4 (en) | 2013-10-16 |
IL249578A0 (en) | 2017-02-28 |
KR101868165B1 (ko) | 2018-07-19 |
RU2591194C2 (ru) | 2016-07-10 |
US20130202692A1 (en) | 2013-08-08 |
WO2011133224A1 (en) | 2011-10-27 |
IL222571A0 (en) | 2012-12-31 |
JP5894574B2 (ja) | 2016-03-30 |
EP2560676B8 (en) | 2016-10-12 |
IL222571A (en) | 2017-12-31 |
IL249578A (en) | 2017-12-31 |
CN103209704A (zh) | 2013-07-17 |
CA2796756A1 (en) | 2011-10-27 |
EP2560676B1 (en) | 2016-08-10 |
JP2013525352A (ja) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012026881A2 (pt) | compostos orgânicos | |
MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
BR112018069594A2 (pt) | compostos orgânicos | |
MX2014012374A (es) | Compuestos organicos. | |
MX2021014508A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
MX2020000968A (es) | Compuestos organicos. | |
MX2016013046A (es) | Compuestos organicos. | |
MX2020000967A (es) | Compuestos organicos. | |
PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
BR112012018232B8 (pt) | Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
CY1120435T1 (el) | Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου | |
CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
UA105229C2 (uk) | Фармацевтичний склад | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
TN2011000585A1 (en) | Lxr modulators | |
UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
TN2010000038A1 (en) | Organic compounds | |
EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
MX2020009929A (es) | Compuestos organicos. | |
PH12015501386A1 (en) | Tricyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |